Our top pick for
Ikena Oncology Inc is a biotechnology business based in the US. Ikena Oncology shares (IKNA) are listed on the NASDAQ and all prices are listed in US Dollars. Ikena Oncology employs 50 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$11.16|
|52-week range||$9.63 - $37.61|
|50-day moving average||$12.81|
|200-day moving average||$15.01|
|Wall St. target price||$27.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-7.84%|
|1 month (2021-09-22)||-14.09%|
|3 months (2021-07-22)||-3.96%|
|6 months (2021-04-22)||-44.28%|
|1 year (2020-10-18)||N/A|
|2 years (2019-10-18)||N/A|
|3 years (2018-10-18)||N/A|
|5 years (2016-10-18)||N/A|
|Revenue TTM||$9.9 million|
|Gross profit TTM||$-24,513,000|
|Return on assets TTM||-16.4%|
|Return on equity TTM||-72.35%|
|Market capitalisation||$509.5 million|
TTM: trailing 12 months
There are currently 1.3 million Ikena Oncology shares held short by investors – that's known as Ikena Oncology's "short interest". This figure is 14.4% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting Ikena Oncology shares can be evaluated.
Ikena Oncology's "short interest ratio" (SIR) is the quantity of Ikena Oncology shares currently shorted divided by the average quantity of Ikena Oncology shares traded daily (recently around 97940.314136126). Ikena Oncology's SIR currently stands at 13.37. In other words for every 100,000 Ikena Oncology shares traded daily on the market, roughly 13370 shares are currently held short.
To gain some more context, you can compare Ikena Oncology's short interest ratio against those of similar companies.
However Ikena Oncology's short interest can also be evaluated against the total number of Ikena Oncology shares, or, against the total number of tradable Ikena Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ikena Oncology's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Ikena Oncology shares in existence, roughly 30 shares are currently held short) or 0.086% of the tradable shares (for every 100,000 tradable Ikena Oncology shares, roughly 86 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ikena Oncology.
Find out more about how you can short Ikena Oncology stock.
We're not expecting Ikena Oncology to pay a dividend over the next 12 months.
Ikena Oncology, Inc. , a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.